SEARCH:   Advanced

Blood, 15 February 2004, Vol. 103, No. 4, pp. 1364-1369. Prepublished online as a Blood First Edition Paper on October 23, 2003; DOI 10.1182/blood-2003-08-2672. This Article Full Text (PDF) All Versions of this Article: 2003-08-2672v1 103/4/1364    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by McMillan, R. Articles by Pistillo, J. Search for Related Content PubMed PubMed Citation Articles by McMillan, R. Articles by Pistillo, J. Social Bookmarking                   What's this? Submitted August 5, 2003 Accepted October 16, 2003 Suppression of In Vitro Megakaryocyte Production by Antiplatelet Autoantibodies from Adult Chronic ITP Patients Robert McMillan*, Lei Wang, Aaron Tomer, Janet Nichol, and Jeanne Pistillo The Scripps Research Institute, La Jolla, CA, USA Ben-Gurion University of the Negev, Beer-Sheva, Israel Amgen, Inc., Thousand Oaks, CA, USA * Corresponding author; email: mcmillan{at}scripps.edu. Chronic immune thrombocytopenic purpura (ITP) is manifested by autoantibody-induced platelet destruction. Platelet turnover studies suggest that autoantibody may also affect platelet production. To evaluate this, we studied the effect of plasma from adult chronic ITP patients on in vitro megakaryocyte production. CD34(+) cells, obtained from normal donors, were cultured in medium containing PEG-rHuMGDF and 10% plasma from either ITP patients or normal subjects. Findings. Cultures containing plasma from 12 of 18 ITP patients showed a significant decrease (26 to 95%) in megakaryocyte production when compared to control cultures. Positive ITP plasmas not only reduced the total number of megakaryocytes that were produced during the culture period but also inhibited megakaryocyte maturation, resulting in fewer 4N, 8N and 16N cells. The role of antibody in this suppression is supported by: (a) IgG from ITP patients inhibited megakaryocyte production when compared to control IgG and (b) adsorption of autoantibody, using immobilized antigen, resulted in significantly less inhibition of megakaryocyte production when compared to unadsorbed plasma. These results show that plasma autoantibody from some adult ITP patients inhibits in vitro platelet production suggesting a similar effect may occur in vivo. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. J. Kuter, G. J. Mufti, B. J. Bain, R. P. Hasserjian, W. Davis, and M. Rutstein Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim Blood, October 29, 2009; 114(18): 3748 - 3756. [Abstract] [Full Text] [PDF] D. B. Cines, J. B. Bussel, H. A. Liebman, and E. T. Luning Prak The ITP syndrome: pathogenic and clinical diversity Blood, June 25, 2009; 113(26): 6511 - 6521. [Abstract] [Full Text] [PDF] D. S. Woulfe A Syk inhibitor for sick platelets? Blood, April 2, 2009; 113(14): 3133 - 3134. [Full Text] [PDF] J. B. Bussel, D. J. Kuter, V. Pullarkat, R. M. Lyons, M. Guo, and J. L. Nichol Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP Blood, March 5, 2009; 113(10): 2161 - 2171. [Abstract] [Full Text] [PDF] C. Zhao, X. Li, F. Zhang, L. Wang, J. Peng, and M. Hou Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies Haematologica, September 1, 2008; 93(9): 1428 - 1430. [Full Text] [PDF] J. W. Semple ITP three R's: regulation, routing, rituximab Blood, August 15, 2008; 112(4): 927 - 928. [Full Text] [PDF] B. Olsson, B. Ridell, L. Carlsson, S. Jacobsson, and H. Wadenvik Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1 Blood, August 15, 2008; 112(4): 1078 - 1084. [Abstract] [Full Text] [PDF] T. B. Gernsheimer The Pathophysiology of ITP Revisited: Ineffective Thrombopoiesis and the Emerging Role of Thrombopoietin Receptor Agonists in the Management of Chronic Immune Thrombocytopenic Purpura Hematology, January 1, 2008; 2008(1): 219 - 226. [Abstract] [Full Text] [PDF] G. Emilia, M. Luppi, P. Zucchini, M. Morselli, L. Potenza, F. Forghieri, F. Volzone, G. Jovic, G. Leonardi, A. Donelli, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles Blood, December 1, 2007; 110(12): 3833 - 3841. [Abstract] [Full Text] [PDF] R. S. Schwartz Immune Thrombocytopenic Purpura -- From Agony to Agonist N. Engl. J. Med., November 29, 2007; 357(22): 2299 - 2301. [Full Text] [PDF] D. M. Boruchov, S. Gururangan, M. C. Driscoll, and J. B. Bussel Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP) Blood, November 15, 2007; 110(10): 3526 - 3531. [Abstract] [Full Text] [PDF] J. B. Bussel, D. J. Kuter, J. N. George, R. McMillan, L. M. Aledort, G. T. Conklin, A. E. Lichtin, R. M. Lyons, J. Nieva, J. S. Wasser, et al. AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP N. Engl. J. Med., October 19, 2006; 355(16): 1672 - 1681. [Abstract] [Full Text] [PDF] D. J. Nugent Immune Thrombocytopenic Purpura of Childhood Hematology, January 1, 2006; 2006(1): 97 - 103. [Abstract] [Full Text] [PDF] R. McMillan and C. Durette Long-term outcomes in adults with chronic ITP after splenectomy failure Blood, August 15, 2004; 104(4): 956 - 960. [Abstract] [Full Text] [PDF] D. B. Cines, J. B. Bussel, R. B. McMillan, and J. L. Zehnder Congenital and Acquired Thrombocytopenia Hematology, January 1, 2004; 2004(1): 390 - 406. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020